<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183609</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00075175</org_study_id>
    <nct_id>NCT03183609</nct_id>
  </id_info>
  <brief_title>Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)</brief_title>
  <official_title>Confirmatory Double-Blind Placebo-Controlled Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study purpose is to conduct a confirmatory double-blind randomized controlled trial in&#xD;
      an inpatient setting of the effects of a tightly controlled gluten-free diet (GFD) to improve&#xD;
      negative symptoms in people with schizophrenia or schizoaffective disorder who have&#xD;
      antibodies to gliadin (AGA IgG). As part of the project investigators will also confirm&#xD;
      outcomes such as cognitive symptoms, changes in peripheral and central inflammation as well&#xD;
      as gut/blood brain barrier permeability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized double blind clinical trial being funded by NIMH. Investigators&#xD;
      will need to enroll 40 cases with AGA IgG positivity in order to present a powered and&#xD;
      convincing result about the efficacy of gluten withdrawal in the subpopulation of persons&#xD;
      with schizophrenia with elevated AGA IgG levels. Investigators will recruit a minimum 50 to&#xD;
      ensure they are well powered without question, and to account for dropouts. Investigators&#xD;
      will use a battery of measures of peripheral and central inflammation as well as gut&#xD;
      permeability at baseline and endpoint to confirm the relationship of these outcomes to&#xD;
      changes in AGA IgG and symptom changes in the clinical trial. Investigators will test&#xD;
      negative symptoms as a primary outcome but will test changes in other symptom domains such as&#xD;
      positive symptoms. After the completion of the 5 week confirmatory study, investigators will&#xD;
      discharge participants and follow them for 8 weeks in their own environment to test the&#xD;
      maintenance of the effect following the stringent GFD, and provide education on gluten free&#xD;
      shopping, cooking and eating.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double blind trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative symptom change as defined by difference in Scale for the Assessment of Negative Symptoms (SANS) score</measure>
    <time_frame>5 weeks</time_frame>
    <description>This will be measured by the difference in Scale for the Assessment of Negative Symptoms (SANS) score from baseline to week 5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function as measured by change in MATRICS Consensus Cognitive Battery (MCCB)</measure>
    <time_frame>5 weeks</time_frame>
    <description>This will be measured by the difference in MATRICS Consensus Cognitive Battery (MCCB) scores from baseline to week 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Gluten Sensitivity</condition>
  <condition>Schizo Affective Disorder</condition>
  <arm_group>
    <arm_group_label>Gluten</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 grams of gluten flour daily in protein shake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 grams of rice flour daily in protein shake</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gluten Flour in Protein Shake</intervention_name>
    <description>15 Grams Gluten Flour BID</description>
    <arm_group_label>Gluten</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rice Flour in Protein Shake</intervention_name>
    <description>15 Grams Rice Flour BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. DSM-IV/DSM 5 diagnosis of schizophrenia or schizoaffective disorder&#xD;
&#xD;
          2. Positive for antibodies to gliadin (IgG &gt; 20 U)&#xD;
&#xD;
          3. SANS total score ≥ 20 and the affective flattening or alogia global item ≥ 3&#xD;
&#xD;
          4. Age 18- 64 years&#xD;
&#xD;
          5. Same antipsychotic for at least 4 weeks&#xD;
&#xD;
          6. Ability to consent determined by a score of 10 or greater on the Evaluation to Sign&#xD;
             Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Persons already on gluten free diets&#xD;
&#xD;
          2. Positivity to tissue transglutaminase (tTg) antibodies or known history of Celiac&#xD;
             Disease&#xD;
&#xD;
          3. Pregnant or lactating females&#xD;
&#xD;
          4. Medical condition whose pathology or treatment could alter the presentation or&#xD;
             treatment of schizophrenia or significantly increase the risk associated with the&#xD;
             proposed treatment protocol&#xD;
&#xD;
          5. Meets DSM-5 criteria for alcohol or substance use disorder (other than nicotine)&#xD;
             within the last month&#xD;
&#xD;
          6. Gluten ataxia, as measured by the Brief Ataxia Rating Scale&#xD;
&#xD;
             Additional exclusion for those participating in optional imaging component:&#xD;
&#xD;
          7. Non-removable ferromagnetic metal on or within the body&#xD;
&#xD;
          8. Current claustrophobia&#xD;
&#xD;
          9. Inability to lie supine for 1.5 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ann Keanrs, MS</last_name>
    <phone>410-402-6854</phone>
    <email>akearns@mprc.umaryland.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center (MPRC) Outpatient Research Program (ORP); the MPRC Treatment Research Program (TRP)</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AnnMarie Kearns, BS</last_name>
      <phone>410-402-6854</phone>
      <email>akearns@mprc.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Feldman, MSW</last_name>
      <phone>410-402-6885</phone>
      <email>sfeldman@mprc.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deanna L Kelly, Pharm.D., BCPP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mprc.umaryland.edu</url>
    <description>Maryland Psychiatric Research Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Deanna Kelly</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

